Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Roth

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Blood|September 24, 2004
The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia BAmy D Shapiro, Jorge Di Paola, Alice Cohen, et al.
RMD Open|April 16, 2022
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 yearsFengchun Zhang, Jie Zheng, Yang Li, et al.
Environmental Science & Technology|January 3, 2022
Watershed-Scale Risk to Aquatic Organisms from Complex Chemical Mixtures in the Shenandoah RiverLarry B Barber, Kaycee E Faunce, David W Bertolatus, et al.
Molecular and Biochemical Parasitology|January 1, 2008
Transcriptionally active PCR for antigen identification and vaccine development: in vitro genome-wide screening and in vivo immunogenicityDavid P Regis, Carlota Dobaño, Paola Quiñones-Olson, et al.
Blood Advances|February 28, 2025
A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemiaFarhad Ravandi, Sravanti Rangaraju, Hagop Kantarjian, et al.
Environmental Science. Processes & Impacts|February 5, 2024
Wildland-urban interface wildfire increases metal contributions to stormwater runoff in Paradise, CaliforniaLauren J Magliozzi, Sandrine J Matiasek, Charles N Alpers, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 17, 2019
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus ErythematosusDaniel J Wallace, Ellen M Ginzler, Joan T Merrill, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 4, 2022
Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian PopulationXueqing Yu, Nan Chen, Jun Xue, et al.
The New England Journal of Medicine|September 16, 2020
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus NephritisRichard Furie, Brad H Rovin, Frédéric Houssiau, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 24, 2021
Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus ErythematosusEllen Ginzler, Luiz Sergio Guedes Barbosa, David D'Cruz, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Blood|September 24, 2004
The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia BAmy D Shapiro, Jorge Di Paola, Alice Cohen, et al.
RMD Open|April 16, 2022
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 yearsFengchun Zhang, Jie Zheng, Yang Li, et al.
Environmental Science & Technology|January 3, 2022
Watershed-Scale Risk to Aquatic Organisms from Complex Chemical Mixtures in the Shenandoah RiverLarry B Barber, Kaycee E Faunce, David W Bertolatus, et al.
Molecular and Biochemical Parasitology|January 1, 2008
Transcriptionally active PCR for antigen identification and vaccine development: in vitro genome-wide screening and in vivo immunogenicityDavid P Regis, Carlota Dobaño, Paola Quiñones-Olson, et al.
Blood Advances|February 28, 2025
A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemiaFarhad Ravandi, Sravanti Rangaraju, Hagop Kantarjian, et al.
Environmental Science. Processes & Impacts|February 5, 2024
Wildland-urban interface wildfire increases metal contributions to stormwater runoff in Paradise, CaliforniaLauren J Magliozzi, Sandrine J Matiasek, Charles N Alpers, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 17, 2019
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus ErythematosusDaniel J Wallace, Ellen M Ginzler, Joan T Merrill, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 4, 2022
Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian PopulationXueqing Yu, Nan Chen, Jun Xue, et al.
The New England Journal of Medicine|September 16, 2020
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus NephritisRichard Furie, Brad H Rovin, Frédéric Houssiau, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 24, 2021
Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus ErythematosusEllen Ginzler, Luiz Sergio Guedes Barbosa, David D'Cruz, et al.
Pageof 6